Reports: Wednesday, August 5, 2026, before market open | Conference call ~9:00 AM ET
CRL shares have been on a strong run into the print, climbing from a 52-week low near $150 in mid-May to roughly $234 as of August 4 — a rally of more than 55% off the lows and a move that has pushed the stock back near cycle highs heading into results. That momentum raises the bar for what the market will consider a "good" quarter, particularly since consensus already embeds a sequential earnings inflection that management itself guided to.
Wall Street is looking for Q2 revenue of ~$970.8 million (a ~6% year-over-year decline) and adjusted EPS of ~$2.72 (down ~12.8% year-over-year but up more than 30% sequentially from Q1's $2.06). The Zacks Consensus Estimate for the company's second-quarter revenues is pegged at $970.8 million, suggesting a 5.9% decline from the year-ago reported figure, while the EPS consensus projects a decrease of 12.8% year over year to $2.72, an estimate that dropped 1.1% in the past 30 days. Charles River has a strong beat history — its Q1 2026 adjusted EPS of $2.06 surpassed the Zacks Consensus Estimate by 5.1%, and the company beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 9.31%.
CRL reaffirmed full-year 2026 guidance in May and gave fairly explicit Q2 parameters: - Full-year: organic revenue decline of 0.5%–1.5%, non-GAAP EPS of $10.80–$11.30 (5%–10% growth over 2025), and ~120–150 bps of operating margin expansion, weighted heavily to H2. - Q2 specifically: reported revenue was expected to decline at a mid- to high single-digit rate year-over-year due primarily to the divestitures, with organic revenue projected to decline at a low single-digit rate, similar to Q1 — while earnings per share were expected to improve significantly on a sequential basis, increasing at least 30% from the first quarter level of $2.06, as NHP shipment timing and study-start cost headwinds from Q1 subside and the manufacturing margin benefits from the closed CDMO divestiture flow through.
That guidance lines up almost exactly with the current Street consensus, so the key question for the print isn't really "will they hit the number" (history suggests a modest beat is likely) but whether the margin bridge and demand-trend commentary stay on track for the much larger implied H2 acceleration.
1. DSA bookings and the "return to growth" thesis. Management's full-year guide hinges on DSA organic growth turning positive in H2 2026, supported by book-to-bill above 1x. In Q1, the DSA demand environment remained solid as demonstrated by a net book-to-bill of 1.04x in the first quarter, continuing to support a return to DSA organic revenue growth in the second half of the year, with net bookings totaling a solid $622 million, remaining above the $600 million threshold, driven by continued strength from small and mid-sized biotech clients. Watch for whether Q2 net book-to-bill held above 1.0x and whether biotech bookings — at their highest level in over two years as of Q1 — continued to build, plus commentary on proposal volumes, which had risen sequentially for three straight quarters heading into Q1.
2. Divestiture completion and margin cadence. Two portfolio-reshaping deals were slated to close in Q2: the CDMO/Cell Solutions sale to GI Partners (closed May 6) and the ~$145 million sale of five European Discovery Services sites to IQVIA for approximately $145 million, with the potential for up to $10 million in additional milestone-based payments, covering five European sites and assets that generated $144 million in revenue in 2025, expected to close in May 2026. Confirmation that both deals are fully closed and flowing into margins matters because management said the second half of the year operating margin will be over 500 basis points higher than the first six months of the year, with over half of this improvement being driven by completed acquisitions and divestitures — a big, back-half-loaded margin story investors will want reconfirmed.
3. NHP supply chain and China monkey pricing. A fresh industry data point emerged just before earnings: cynomolgus macaque prices in China have surged to roughly $26,000 each, nearly double year-ago levels, tightening primate supply industry-wide. This is a topical read-through for CRL given its DSA safety-assessment studies rely on NHPs; however, CRL has been actively insulating itself via the Noveprim stake and the newly acquired K.F. Cambodia (Charles River Cambodia) assets, with management noting combined with Noveprim, the company expects to internally source most of its future NHP supply requirements for the DSA segment. Watch for updates on internal NHP sourcing progress and whether Q1's elevated "NHP sourcing costs and study starts" headwind in DSA margins is fully abating as promised.
4. Global pharma vs. biotech demand mix. Q1 showed revenue from global biopharmaceutical clients increasing, while revenue from small and mid-sized biotechs declined, primarily reflecting softer DSA booking activity last summer and a normal lag between booking and revenue generation, with management expecting the revenue trend to improve in upcoming quarters. Confirmation that biotech revenue is inflecting positively (as opposed to just bookings) would be a meaningful positive signal.
5. New leadership commentary and September Investor Day. This is only new CEO Birgit Girshick's second call and new CFO Glenn Coleman's first full quarter leading financials. Their "Pathway to Purpose" strategic framework — a disciplined approach to driving growth and shareholder value through modernizing the company, strengthening the scientific portfolio, and client-centric go-to-market execution — will get its full unveiling at a September Investor Day, so Q2 commentary may be relatively light on new long-term targets, with more detail deferred. Listen for any preview of 2027 framing, given management already quantified roughly $0.50–$0.55 of EPS accretion from acquisitions and divestitures in 2027 versus 2026.
6. Capital allocation. CRL repurchased approximately 1.1 million shares for $200.0 million in Q1 2026, leaving $800.0 million remaining under its $1.0 billion authorization approved last October. Continued buyback pace would reinforce the EPS bridge, particularly given FX has become a modest headwind to reported revenue this year.
7. RMS segment and China research models. RMS has been the weakest link, with Q1 organic revenue down 5.5% due primarily to lower revenue for small research models in North America and for NHPs due to the timing of shipments, partially offset by solid demand for small models in China from mid-tier biotech and CRO clients. Guidance calls for RMS large-model/NHP shipment timing to have troughed in Q1, so a sequential RMS margin recovery is expected; a miss here would be a red flag on the overall margin bridge.
The stock's sharp rally has pushed it toward the top end (and in some cases above) sell-side price targets — one recent Seeking Alpha-sourced view downgraded CRL to "Sell" as shares rallied 57% in the past year, outpacing fundamentals, noting that despite Q1 stabilization, organic revenue declined and margins compressed, with CRL trading at roughly 17.5x forward earnings — still a discount to its history but not cheap, recommending investors take profits given limited growth and potential AI-driven disruption risk. Consensus sell-side sentiment remains more constructive overall, with a majority of covering analysts at Buy/Strong Buy, but price targets are clustered in the low-to-mid $200s — meaning current levels leave less margin for error than earlier in the year.
This print is less about whether CRL clears a low bar (consensus already reflects management's own guidance for a sharp sequential EPS jump) and more about whether the narrative underpinning H2 acceleration stays intact: DSA book-to-bill above 1x, biotech bookings converting to revenue, both divestitures fully closed and accretive, and the ~500bp H1-to-H2 margin step-up bridge remaining credible. Given the stock's already-large run-up, a "good enough" quarter that merely confirms the plan may not be sufficient to keep multiple expansion going — investors will be parsing management's tone on Q3/Q4 confidence and any incremental color ahead of September's Investor Day just as closely as the reported numbers.